Preferred treatment options for patients with accelerated phase CML include second- or third-generation TKIs (bosutinib, dasatinib, nilotinib, or ponatinib). The first-generation TKI, imatinib, or the protein synthesis inhibitor, omacetaxine, may be considered for patients in whom a second- or third-generation TKI is contraindicated or resisted.
Learn more about medications used in the management of CML.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Chronic Myelogenous Leukemia Management - Medscape - Sep 21, 2022.